GSK3532795

GSK3532795 (BMS-955176) is a potent, orally active, second-generation HIV-1 maturation inhibitor, with EC50s of 1.9, 10.2, 2.7 and 13 nM for HIV-1 WT, HIV-1 WT (human serum), HIV-1 V370A, and HIV-1 ΔV370, respectively[1].

Product Specifications

CAS Number

[1392312-45-6]

Product Name Alternative

BMS-955176

UNSPSC

12352005

Target

HIV

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/gsk3532795.html

Purity

99.59

Solubility

10 mM in DMSO

Smiles

CC1(C)C(C2=CC=C(C(O)=O)C=C2)=CC[C@@]3(C)[C@@]1([H])CC[C@]4(C)[C@]3([H])CC[C@@]5([H])[C@@]4(C)CC[C@]6(NCCN7CCS(CC7)(=O)=O)[C@]5([H])[C@H](C(C)=C)CC6

Molecular Formula

C42H62N2O4S

Molecular Weight

691.02

References & Citations

[1]Regueiro-Ren A, et al. Design, Synthesis, and SAR of C-3 Benzoic Acid, C-17 Triterpenoid Derivatives. Identification of the HIV-1 Maturation Inhibitor 4- ((1 R,3a S,5a R,5b R,7a R,11a S,11b R,13a R,13b R) -3a- ((2- (1,1-Dioxidothiomorpholino) ethyl) amino) -5a,5b,8,8,11a-pentamethyl-1- (prop-1-en-2-yl) -2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1 H-cyclopenta[ a]chrysen-9-yl) benzoic Acid (GSK3532795, BMS-955176) . J Med Chem. 2018 Aug 23;61 (16) :7289-7313.